Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis
Yuji Oba, Nazir A Lone
University of Missouri, School of Medicine, Division of Pulmonary, Critical Care and Environmental Medicine, Columbia, MO, USA
Background: A combination therapy with inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA) is recommended in severe chronic obstructive pulmonary disease (COPD) patients experiencing frequent exacerbations. Currently, there are five ICS/LABA combination products available on the market. The purpose of this study was to systematically review the efficacy of various ICS/LABA combinations with a network meta-analysis.
Methods: Several databases and manufacturer's websites were searched for relevant clinical trials. Randomized control trials, at least 12 weeks duration, comparing an ICS/LABA combination with active control or placebo were included. Moderate and severe exacerbations were chosen as the outcome assessment criteria. The primary analyses were conducted with a Bayesian Markov chain Monte Carlo method.
Results: Most of the ICS/LABA combinations reduced moderate-to-severe exacerbations as compared with placebo and LABA, but none of them reduced severe exacerbations. However, many studies excluded patients receiving long-term oxygen therapy. Moderate-dose ICS was as effective as high-dose ICS in reducing exacerbations when combined with LABA.
Conclusion: ICS/LABA combinations had a class effect with regard to the prevention of COPD exacerbations. Moderate-dose ICS/LABA combination therapy would be sufficient for COPD patients when indicated. The efficacy of ICS/LABA combination therapy appeared modest and had no impact in reducing severe exacerbations. Further studies are needed to evaluate the efficacy of ICS/LABA combination therapy in severely affected COPD patients requiring long-term oxygen therapy.
Keywords: combination therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Other article by this author:
Yuji Oba, Tareq Zaza, Danish M Thameem
Published Date: 5 December 2008
Readers of this article also read:
Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study
Wurst KE, St Laurent S, Mullerova H, Davis KJ
Published Date: 25 September 2014
Pini L, Pinelli V, Modina D, Bezzi M, Tiberio L, Tantucci C
Published Date: 1 September 2014
Chronic disease self-management and exercise in COPD as pulmonary rehabilitation: a randomized controlled trial
Cameron-Tucker HL, Wood-Baker R, Owen C, Joseph L, Walters EH
Published Date: 19 May 2014
Does the duration of smoking cessation have an impact on hospital admission and health-related quality of life amongst COPD patients?
Hassan HA, Aziz NA, Hassan Y, Hassan F
Published Date: 14 May 2014
Woods JA, Wheeler JS, Finch CK, Pinner NA
Published Date: 3 May 2014
Reid DJ, Carlson AA
Published Date: 28 April 2014
Assessment of patients' preferences regarding the characteristics associated with the treatment of chronic obstructive pulmonary disease
Bulcun E, Ekici M, Ekici A
Published Date: 16 April 2014
Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
Published Date: 1 April 2014
Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease
Nishimura K, Nishimura T, Onishi K, Oga T, Hasegawa Y, Jones PW
Published Date: 5 February 2014
Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis
Karabis A, Lindner L, Mocarski M, Huisman E, Greening A
Published Date: 9 September 2013